ClinicalTrials.gg
CompletedNCT07069309Updated Jun 1, 2026

A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years

A Phase 3 interventional study of BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) in COVID-19 and SARS-COV-2 Infection, sponsored by BioNTech SE. Completed at 19 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by BioNTech SE · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
774
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.

Enrollment
18th of 54
774 · median 575
Started
2025
with 3 others
Phase 3
18 of 54
1 open now
Registered
50th of 54
by date
Lead sponsor
20 of 54
BioNTech SE

Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 18th largest by enrollment, is one of 4 that started in 2025, is one of 18 in phase 3, and was the 50th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About BNT162 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing BNT162 Vaccine in COVID-19, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19.

This study is seeking participants 12 through 64 years of age who are considered to be at higher risk for severe COVID-19 disease per study protocol and those 65 years of age and older. All participants in this study will receive 1 shot to their arm of a BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) 30 µg RNA-based vaccine which targets a circulating variant of SARS-CoV-2 and is selected for the 2025-2026 COVID-19 respiratory virus season. This study is about 6 months for each participant. Participants will either be enrolled in Cohort 1 (Groups 1 and 2) or Cohort 2 (Groups 3 and 4). Participants enrolled in Cohort 1 will have at least 4 visits and participants enrolled in Cohort 2 will have at least 3 visits.

03

Conditions studied

  • COVID-19
  • SARS-COV-2 Infection

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cohort 1: Participants 18 years of age or older.
  • Cohort 2: Participants 12 years of age or older.
  • Participants 12 through 64 years of age with at least 1 underlying medical condition that increases their risk of severe COVID-19.

Exclusion criteria

Exclusion Criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
  • History of myocarditis or pericarditis.
  • Cohort 2: Receipt of a COVID-19 vaccine or a confirmed case of COVID-19 (confirmed by signs/symptoms and/or a positive test result based on local testing) less than 5 months (150 days) prior to study enrollment.

Refer to the study contact for further eligibility details.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
774 participants (actual)

Study arms

  • Experimental
    Group 1: 18 through 64 years of age (higher-risk individuals)

    Participants will receive BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) 30 µg at Visit 1

    Biological: BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)

  • Experimental
    Group 2: 65 years of age and older

    Participants will receive BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) 30 µg at Visit 1

    Biological: BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)

  • Experimental
    Group 3: 12 through 64 years of age (higher-risk individuals)

    Participants will receive BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) 30 µg at Visit 1

    Biological: BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)

  • Experimental
    Group 4: 65 years of age and older

    Participants will receive BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) 30 µg at Visit 1

    Biological: BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)

Interventions

  • BiologicalBNT162b2 (2025/2026 recommended SARS-CoV-2 strain)

    Drug page: BNT162 Vaccine

    BNT162b2 monovalent (2025/2026 recommended SARS-CoV-2 strain)

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting local reactions

    Time frame: For up to 7 days after vaccination

  2. Percentage of participants reporting systemic events

    Time frame: For up to 7 days after vaccination

  3. Percentage of participants reporting adverse events

    Time frame: Through 1 month after vaccination

  4. Percentage of participants reporting serious adverse events

    Time frame: Through 6 months after vaccination

  5. Cohort 1: Geometric Mean Titers (GMTs)

    Time frame: At 2 weeks after vaccination

  6. Cohort 1: Geometric Mean Fold Rises (GMFRs)

    Time frame: From before vaccination to 2 weeks after vaccination

  7. Cohort 1: Percentages of participants with seroresponse

    Time frame: 2 weeks after vaccination

  8. Cohort 2: Geometric Mean Fold Rises (GMFRs)

    Time frame: From before vaccination to 1 month after vaccination

Secondary outcomes

  1. Cohort 1: Geometric Mean Titers (GMTs)

    Time frame: At 1 month after vaccination

  2. Cohort 1: Geometric Mean Fold Rises (GMFRs)

    Time frame: From before vaccination to 1 month after vaccination

  3. Cohort 1: Percentages of participants with seroresponse

    Time frame: 1 month after vaccination

  4. Cohort 2: Geometric Mean Titers (GMTs)

    Time frame: From before vaccination to 1 month after vaccination

  5. Cohort 2: Percentages of participants with seroresponse

    Time frame: 1 month after vaccination

07

Study locations

19 sites
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Clinical Research Consulting
    Milford, Connecticut 06460, United States
  • GW Vaccine Research Unit
    Washington D.C., District of Columbia 20037, United States
  • The GW Medical Faculty Associates
    Washington D.C., District of Columbia 20037, United States
  • Indago Research & Health Center, Inc
    Hialeah, Florida 33012, United States
  • Palm Springs Community Health Center
    Miami Lakes, Florida 33014, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Kentucky Pediatric/ Adult Research
    Bardstown, Kentucky 40004, United States
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO
    Springfield, Missouri 65802, United States
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO-Screening and Recruitment Center
    Springfield, Missouri 65807, United States
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
  • Accellacare - Wilmington
    Wilmington, North Carolina 28401, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Senders Pediatrics
    South Euclid, Ohio 44121, United States
  • DM Clinical Research - Philadelphia
    Philadelphia, Pennsylvania 19107, United States
  • DM Clinical Research- Cyfair
    Houston, Texas 77065, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22911, United States
08

References and documents

Publications

  • Dadhe R, Gayed J, Iqbal M, Solan R, Wu H, Ma H, Xu X, Mensa FJ, Belanger T, Cooper D, Mogg R, Anderson AS, Tureci O, Sahin U, Allen PS, Modjarrad K, Gurtman A, Lindert K. A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults >/= 65 Years of Age and High-Risk Adults 18-64 Years of Age (Preliminary Results). Vaccines (Basel). 2026 Apr 15;14(4):350. doi: 10.3390/vaccines14040350. PubMed 42042826 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in May 2026, 9 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 9 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Jul 16, 2025
StartActual
Jul 8, 2025
Primary completionActual
May 1, 2026
CompletionActual
May 1, 2026
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07069309
Lead sponsor
BioNTech SE
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jul 16, 2025
Start date
Jul 8, 2025
Primary completion
May 1, 2026
Completion
May 1, 2026
Last update
Jun 1, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion